Safety and Reactogenicity of the Inactivated Poliomyelitis Vaccine (Poliorix(TM)) in Korea (2006-2012).
- Author:
Jong Beom SIN
1
;
Moon Sung PARK
;
Sang Hyuk MA
;
Young Youn CHOI
;
Son Moon SHIN
;
Won Duck KIM
;
Sherine KURIYAKOSE
;
Liliana ULIANOV
;
Karin HARDT
Author Information
1. Department of Pediatrics, Busan Paik Hospital, Inje University College of Medicne, Busan, Korea. pedsin@inje.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Poliomyelitis;
Inactivated polio vaccine;
Safety;
Reactogenicity;
Korea
- MeSH:
Child;
Follow-Up Studies;
Humans;
Infant;
Korea*;
Parents;
Poliomyelitis*;
Respiratory Tract Infections;
United States Food and Drug Administration;
Vaccination
- From:Korean Journal of Pediatric Infectious Diseases
2013;20(3):139-146
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: As per the requirement of Korean Food and Drug Administration, this post-marketing surveillance was conducted in Korea to evaluate the safety and reactogenicity of Poliorix(TM) following its introduction in 2006. METHODS: In this open, multicenter study, the vaccine was administered as per the current practice of Korean doctors and in reference to the guidebook by the Korean Pediatric Society and as indicated in the Korean label which was as follows - for primary vaccination three doses were given to infants at ages 2, 4 and 6 months whereas, for the booster dose a single dose was given to children aged 4-6 years. Safety data during this six year surveillance was collected using diary cards which were distributed to the parents to record adverse events. RESULTS: A total of 639 subjects were enrolled into the study. Of these, 617 subjects and 22 subjects received the vaccine as a primary and booster dose, respectively. At least one unsolicited symptom was reported in 11.4% (73/639) of the subjects during the 7-day follow-up period; upper respiratory tract infection (2.5%;16/639) was the most frequently reported unsolicited symptom. One subject reported at least one unsolicited symptom (gastroenteritis) of grade 3 intensity within the 31-day post-vaccination period. Approximately 1.7% (11/639) of subjects reported 13 serious adverse events (SAEs). All SAEs were resolved by the end of the study. CONCLUSION: In Korea, primary and booster vaccination with Poliorix(TM) was well-tolerated in healthy subjects when administered according to the prescribing information as part of routine clinical practice.
